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Achromobacter xylosoxidans, subspecies denitrificans, is a gram-negative rod recently implicated as an emerging cause of infection in
both immunosuppressed and immunocompetent populations. Few cases are reported in literature involvingmultiple body systems.
Diagnosis depends on cultures of appropriate specimens, and management usually is by administration of appropriate antibiotics
(usually agents with antipseudomonal activity).We report a rare case of pneumonia due to infection with this organism, in a patient
with preexisting bronchiectasis secondary to chronic aspiration.
1. Introduction
Achromobacter xylosoxidans subspecies denitrificans is a
gram-negative bacillus recently emerging as a causative agent
of infection [1]. The Achromobacter species has many sub-
species the most clinically important of which are xylosox-
idans and denitrificans [1]. There are infrequent reports
of infections with this organism involving various organs
(Table 1). It seems that a dysfunctional immune status and/or
prior structural damage plays a role in the pathogenicity
Achromobacter xylosoxidans, subspecies denitrificans. We
report a rare case of pneumonia due to this organism in a 45-
year-old female with bronchiectasis secondary to recurrent
aspiration.
2. Case Presentation
This is a 45-year-old White female with past medical his-
tory of asthma and gastroesophageal reflux disease (GERD)
treated with Nissen fundoplication in the past. She pre-
sented to our clinic with chronic cough productive of
greenish sputum. She improved with previous antibiotic
use of levofloxacin on several occasions but her symptoms
would recur as soon as she stops the antibiotics. Chest
X-ray at initial evaluation showed an infiltrate bilaterally
more pronounced on the right lower lobe. A CT scan of
the chest was obtained and confirmed the infiltrates and
showed bronchiectatic changes bilaterally in the lower lobes
(Figure 1). Her autoimmune screen came back negative
for rheumatoid arthritis and Sjogren’s syndromes, yet her
immunoglobulins were elevated and her alpha one antit-
rypsin and immunoglobulin E (IgE) were at normal levels.
Her sweat chloride test was normal. Chronic recurrent
aspiration was suspected and an esophageal PH monitor
along with esophageal manometry confirmed our suspicion
of chronic aspiration secondary to severe acid reflux with
elevated DeMeester score. Bronchoscopy was performed
to rule out an obstructive disease and to obtain samples
to rule out mycobacterial disease. Cultures came back
positive for heavy growth of a nonfermenter later identi-
fied as Achromobacter xylosoxidans, subspecies denitrificans.
Sensitivities were evaluated and the bacteria was sensitive
to levofloxacin, amikacin, cefepime, ceftazidime, gentam-
icin, meropenem, piperacillin/tazobactam, tobramycin, and
trimethoprim-sulfamethoxazole. It was found to be resistant
to aztreonam, cefotaxime, and ciprofloxacin, with incubation
period of 5 days. Airway clearance techniques with percus-
sion and flutter valve and bronchodilator therapy with hyper-
tonic saline nebulizers were initiated. She was started on a 3-
week course of levofloxacin but her symptoms recurred one
month after stopping the antibiotic despite airway clearance
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Figure 1: Infiltrates and bronchiectatic changes in lower lobes
bilaterally.
techniques. She was started again on levofloxacin for two
more weeks with good clinical response and no recurrence
of symptoms after a total 5 weeks of antibiotic therapy. She
was referred for surgical intervention to abolish the ongoing
injury to the airway and stop the aspiration insult to the
airways.
3. Discussion
Achromobacter denitrificans is an aerobic, nonglucose fer-
menter gram-negative bacillus and flagellated andmotile and
produces acid from xylose [1]. The genus Achromobacter
has multiple subspecies: xylosoxidans, ruhlandii, piechaudii,
denitrificans, spanius, insolitus, and marplatensis. The most
clinically significant subspecies are Achromobacter xylosoxi-
dans and denitrificans [2]. It can be found in nature in soil,
and the xylosoxidans subspecies has an affinity for aquatic
surfaces. There are more clinically significant isolates of the
subspecies xylosoxidans compared to denitrificans in terms
of incidence of infection and clinical variety. Reports about
infections with Achromobacter denitrificans are rare as an
emerging pathogen.
There is a multitude of respiratory system infection
cases due toAchromobacter xylosoxidans, subspecies xylosox-
idans but not denitrificans [3]. The first reported pneumo-
nia case due to Achromobacter denitrificans was reported
from India in a 48-year-old male clerk in a chemical fac-
tory. It was isolated from sputum at two different occa-
sions with no other concomitant isolates. It was sensitive
to meropenem, imipenem, piperacillin-tazobactam, ticar-
cillin, trimethoprim-sulfamethoxazole, and third-generation
cephalosporins. It was successfully treated with two weeks
of meropenem [4]. Our case is to date the second reported
case of Achromobacter xylosoxidans subspecies denitrificans.
Other reported infections in adults include meningitis [5],
endocarditis [6], endocarditis with aortic root abscess [7],
renal abscess [8], peritoneal dialysis catheter related peritoni-
tis [9], and exit site infection [10] (Table 1).
Diagnosis depends on isolation of the organism depend-
ing on site of the infection. So far, we have reported iso-
lates from septum, pus, peritoneal fluid, and cerebrospinal
fluid (Table 1). Identification can be via standard cultur-
ing methods. In our case bronchoalveolar lavage samples
have been incubated in Blood Agar (TSA with 5% Sheep
Blood)/MacConkey Agar Plate using a BioMe´rieux VITEK-2
system, incubated at 36-37 degrees Celsius.
The immunosuppressed population are at higher risk of
infection due to Achromobacter species [3], yet as seen in
Table 1 most of the patients had not been overtly immuno-
compromised but may have had predisposing conditions
(end stage renal disease, presence of catheters, etc.). Both
cases with involvement of respiratory system had a back-
ground of bronchiectasis.The former [4] was most likely sec-
ondary to tuberculosis while in our case it is most likely sec-
ondary to recurrent aspiration.We theorize that the damaged
bronchiectatic lung tissue predisposed to the infection with
this organism.This had been illustrated before in that Achro-
mobacter species is known to colonize and infect cystic fibro-
sis patients [11]. In the other reported cases (Table 1), we can
notice that structural damage and/or foreign body had been
present: previous trauma, prosthetic valve, peritoneal dialysis
catheter, and renal stones. Pathogenicity of Achromobacter
species has been previously studied [12] with demonstrated
ability to form biofilms and motility (via pili and flagella)
which can potentiate infections in setting of structural
damage and devices.
Management depends on administration of appropriate
antibacterial agents, yet duration of treatment is not exactly
defined due to lack in specific guidelines in this regard.
The cases reported so far (Table 1) had been managed with
different regimens but the most palpable response was to
carbapenems with durations ranging from 2 to 14 weeks
(Table 1). The sensitivity of the isolates is outlined below in
Table 1, but the Achromobacter species had been historically
responsive to antipseudomonal agents [1] with various suc-
cess rates depending on site of infection and complexity of the
cases. Our patient was cured after 5 weeks of oral levofloxacin
therapy (after initial failure after three weeks). The outcome
is generally excellent with clearance of the infection.
4. Conclusion
Rare causes of pneumonia should be investigated since appro-
priate detection can facilitate accurate antibacterial manage-
ment. We theorize that structural damage (bronchiectasis
secondary to chronic aspiration) plays a role in the patho-
genesis of pneumonia in our patient. Combinedmanagement
with antibiotics and airway clearance techniques resulted in
an excellent outcome.
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